Skip to main content

Table 1 The patients’ characteristics and laboratory parameters at CVVH start between the two groups

From: Feasibility and efficacy of modified fixed citrate concentration protocol using only commercial preparations in critically ill patients: a prospective cohort study with a historical control group

Variables

Fixed group (n = 66)

Titrated group (n = 64)

P value

Age, years, mean (SD)

62.7 (18.4)

64.1 (17.6)

0.379

Female gender, n (%)

24 (36.4)

22 (34.4)

0.813

Body weight, kg, median (IQR)

69.2 (61.5–74.3)

70.5 (63.5–74.5)

0.852

Comorbidities, n (%)

 Chronic kidney disease a

13 (19.7)

12 (18.8)

0.891

 Dialysis-dependent

6 (9.1)

2 (3.1)

0.157

 Diabetes mellitus

14 (21.2)

17(26.6)

0.474

 Hypertension

19 (28.8)

16 (25.0)

0.626

 Liver dysfunction b

1 (1.5)

1 (1.6)

0.983

 Cardiac insufficiency c

3 (4.5)

3 (4.7)

0.969

Severity of illness

 APACHE II score, mean (SD)

23.1 (6.8)

22.7 (6.4)

0.541

 SOFA score, mean (SD)

8.0 (2.7)

8.3 (2.3)

0.672

 Vasopressors, n (%)

58 (87.9)

57 (89.1)

0.833

 Mechanical ventilation, n (%)

60 (90.9)

58 (90.6)

0.955

Indication for CVVH, n (%)

 Sepsis-induced AKI

54 (81.8)

55 (85.9)

0.523

 Fluid overload

5 (7.6)

5 (7.8)

0.960

 Tumorlysis syndrome

4 (6.1)

2 (3.1)

0.425

 Others

3 (4.5)

2 (3.1)

0.674

Application of LMWH, n (%)

19(28.8)

24(37.5)

0.352

Laboratory parameters

 Hemoglobin, g/L, mean (SD)

89.1 (19.2)

85.5 (19.7)

0.573

 Platelet count, 109/L, median (IQR)

74.1 (50.7–97.5)

81.5 (60.8–102.2)

0.153

 APTT, S, mean (SD)

42.6 (8.7)

43.2 (8.1)

0.754

 PT, S, mean (SD)

14.0 (2.7)

14.6 (2.3)

0.805

 Serum albumin, g/L, mean (SD)

23.3 (2.4)

24.7 (3.5)

0.672

 Bilirubin, mmol/l, mean (SD)

29.4 (7.5)

27.0 (10.8)

0.718

 ALT, U/L, mean (SD)

68 (28.8)

56 (25.5)

0.182

 Creatinine, μmol/l, median (IQR)

229 (169–559)

240 (143–497)

0.756

 Urea, mmol/l, median (IQR)

33.9 (15.6)

30.8 (14.7)

0.347

 Lactate, mmol/l, median (IQR)

4.8 (2.7–6.8)

4.5 (3.1–6.3)

0.498

 ICU death at 28 days, n (%)

20 (30.3)

22 (34.4)

0.239

  1. Abbreviations: AKI acute renal injury, ALT Alanine Aminotransferease, APACHE, acute physiology and chronic health evaluation, APTT activated partial thromboplastin time, CVVH continuous veno-venous hemofiltration, ICU Intensive Care Unit; IQR interquartile range, LMWH low molecular weight heparin, PT prothrombin time, RCA regional citrate anticoagulation, SD standard deviation, SOFA Sequential Organ Failure Assessment
  2. a Chronic kidney disease defined as stage 3–5 according to Kidney Disease Improving Global outcome in 2012;
  3. b liver dysfunction defined as Child-pugh B-C stage
  4. c Chronic cardiac insufficiency defined of stage III-IV according to New York Heart Association
Back to article page

BMC Anesthesiology

ISSN: 1471-2253

Contact us